{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T03:04:24Z","timestamp":1790996664957,"version":"4.1.0"},"reference-count":127,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmacology"],"published-print":{"date-parts":[[2019,7]]},"DOI":"10.1016\/j.ejphar.2019.05.004","type":"journal-article","created":{"date-parts":[[2019,5,6]],"date-time":"2019-05-06T09:05:06Z","timestamp":1557133506000},"page":"149-159","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":27,"special_numbering":"C","title":["Pathophysiological clues to therapeutic applications of glutamate mGlu5 receptor antagonists in levodopa-induced dyskinesia"],"prefix":"10.1016","volume":"855","author":[{"given":"Shayan","family":"Pourmirbabaei","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahsa","family":"Dolatshahi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farzaneh","family":"Rahmani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejphar.2019.05.004_bib1","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1002\/mds.1090","article-title":"Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature","volume":"16","author":"Ahlskog","year":"2001","journal-title":"Mov. Disord. : official journal of the Movement Disorder Society"},{"key":"10.1016\/j.ejphar.2019.05.004_bib2","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.bbr.2015.01.009","article-title":"Relevance of the metabotropic glutamate receptor (mGluR5) in the regulation of NREM-REM sleep cycle and homeostasis: evidence from mGluR5 (-\/-) mice","volume":"282","author":"Ahnaou","year":"2015","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.ejphar.2019.05.004_bib3","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.jsbmb.2016.02.004","article-title":"Estrogen receptors modulate striatal metabotropic receptor type 5 in intact and MPTP male mice model of Parkinson's disease","volume":"161","author":"Al-Sweidi","year":"2016","journal-title":"J. Steroid Biochem. Mol. Biol."},{"key":"10.1016\/j.ejphar.2019.05.004_bib4","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1006\/nbdi.1999.0259","article-title":"Striatal fosB expression is causally linked with l-DOPA-induced abnormal involuntary movements and the associated upregulation of striatal prodynorphin mRNA in a rat model of Parkinson's disease","volume":"6","author":"Andersson","year":"1999","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.ejphar.2019.05.004_bib5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.nbd.2005.09.010","article-title":"Prolonged blockade of NMDA or mGluR5 glutamate receptors reduces nigrostriatal degeneration while inducing selective metabolic changes in the basal ganglia circuitry in a rodent model of Parkinson's disease","volume":"22","author":"Armentero","year":"2006","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.ejphar.2019.05.004_bib6","doi-asserted-by":"crossref","first-page":"7871","DOI":"10.1523\/JNEUROSCI.20-21-07871.2000","article-title":"Activation of metabotropic glutamate receptor 5 has direct excitatory effects and potentiates NMDA receptor currents in neurons of the subthalamic nucleus","volume":"20","author":"Awad","year":"2000","journal-title":"J. Neurosci. : the official journal of the Society for Neuroscience"},{"key":"10.1016\/j.ejphar.2019.05.004_bib7","series-title":"N-methyl-D-aspartate Receptors Are Critical for Mediating the Effects of Glutamate on Intracellular Calcium Concentration and Immediate Early Gene Expression in Cultured Hippocampal Neurons","author":"Bading","year":"1995"},{"key":"10.1016\/j.ejphar.2019.05.004_bib8","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1007\/s00429-011-0317-x","article-title":"Glutamatergic and cholinergic pedunculopontine neurons innervate the thalamic parafascicular nucleus in rats: changes following experimental parkinsonism","volume":"216","author":"Barroso-Chinea","year":"2011","journal-title":"Brain Struct. Funct."},{"key":"10.1016\/j.ejphar.2019.05.004_bib9","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.nbd.2013.09.020","article-title":"Immediate-early gene expression in structures outside the basal ganglia is associated to l-DOPA-induced dyskinesia","volume":"62","author":"Bastide","year":"2014","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.ejphar.2019.05.004_bib10","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.pneurobio.2015.07.002","article-title":"Pathophysiology of L-dopa-induced motor and non-motor complications in Parkinson's disease","volume":"132","author":"Bastide","year":"2015","journal-title":"Prog. Neurobiol."},{"key":"10.1016\/j.ejphar.2019.05.004_bib11","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1523\/JNEUROSCI.3831-03.2004","article-title":"Endogenous activation of mGlu5 metabotropic glutamate receptors contributes to the development of nigro-striatal damage induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mice","volume":"24","author":"Battaglia","year":"2004","journal-title":"J. Neurosci. : the official journal of the Society for Neuroscience"},{"key":"10.1016\/j.ejphar.2019.05.004_bib12","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1002\/mds.23616","article-title":"AFQ056 treatment of levodopa-induced dyskinesias: results of 2 randomized controlled trials","volume":"26","author":"Berg","year":"2011","journal-title":"Mov. Disord. : official journal of the Movement Disorder Society"},{"key":"10.1016\/j.ejphar.2019.05.004_bib13","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1038\/35086062","article-title":"Pathophysiology of levodopa-induced dyskinesia: potential for new therapies","volume":"2","author":"Bezard","year":"2001","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.ejphar.2019.05.004_bib14","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1002\/mds.25920","article-title":"The mGluR5 negative allosteric modulator dipraglurant reduces dyskinesia in the MPTP macaque model","volume":"29","author":"Bezard","year":"2014","journal-title":"Mov. Disord. : official journal of the Movement Disorder Society"},{"key":"10.1016\/j.ejphar.2019.05.004_bib15","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1002\/mds.870130507","article-title":"Amantadine reduces levodopa-induced dyskinesias in parkinsonian monkeys","volume":"13","author":"Blanchet","year":"1998","journal-title":"Mov. Disord. : official journal of the Movement Disorder Society"},{"key":"10.1016\/j.ejphar.2019.05.004_bib16","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1093\/brain\/124.3.546","article-title":"Dopamine agonist-induced dyskinesias are correlated to both firing pattern and frequency alterations of pallidal neurones in the MPTP-treated monkey","volume":"124","author":"Boraud","year":"2001","journal-title":"Brain : J. Neurol."},{"key":"10.1016\/j.ejphar.2019.05.004_bib17","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1136\/bmj.3.5777.729","article-title":"Idiopathic Parkinsonism treated with an extracerebral decarboxylase inhibitor in combination with levodopa","volume":"3","author":"Calne","year":"1971","journal-title":"Br. Med. J."},{"key":"10.1016\/j.ejphar.2019.05.004_bib18","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.nbd.2003.07.003","article-title":"Levodopa-induced motor complications are associated with alterations of glutamate receptors in Parkinson's disease","volume":"14","author":"Calon","year":"2003","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.ejphar.2019.05.004_bib19","doi-asserted-by":"crossref","first-page":"2563","DOI":"10.1046\/j.1460-9568.2003.02983.x","article-title":"Selective modifications in GAD67 mRNA levels in striatonigral and striatopallidal pathways correlate to dopamine agonist priming in 6-hydroxydopamine-lesioned rats","volume":"18","author":"Carta","year":"2003","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.ejphar.2019.05.004_bib20","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1111\/j.1460-9568.2005.03944.x","article-title":"Different responsiveness of striatonigral and striatopallidal neurons to L-DOPA after a subchronic intermittent L-DOPA treatment","volume":"21","author":"Carta","year":"2005","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.ejphar.2019.05.004_bib21","first-page":"2694","article-title":"L-DOPA-induced dyskinesia in the rat is associated with striatal overexpression of prodynorphin- and glutamic acid decarboxylase mRNA","volume":"10","author":"Cenci","year":"1998","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.ejphar.2019.05.004_bib22","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1111\/j.1471-4159.2006.04124.x","article-title":"Post\u2010 versus presynaptic plasticity in L\u2010DOPA\u2010induced dyskinesia","volume":"99","author":"Cenci","year":"2006","journal-title":"J. Neurochem."},{"issue":"Suppl. 4","key":"10.1016\/j.ejphar.2019.05.004_bib23","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.1016\/S1353-8020(09)70828-4","article-title":"Rodent models of treatment-induced motor complications in Parkinson's disease","volume":"15","author":"Cenci","year":"2009","journal-title":"Park. Relat. Disord."},{"key":"10.1016\/j.ejphar.2019.05.004_bib24","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1080\/13543784.2017.1333598","article-title":"Investigational drugs in phase I and phase II for levodopa-induced dyskinesias","volume":"26","author":"Cerri","year":"2017","journal-title":"Expert Opin. Investig. Drugs"},{"key":"10.1016\/j.ejphar.2019.05.004_bib25","doi-asserted-by":"crossref","first-page":"S86","DOI":"10.1016\/S1471-1931(00)00018-5","article-title":"Striatal dopamine- and glutamate-mediated dysregulation in experimental parkinsonism","volume":"23","author":"Chase","year":"2000","journal-title":"Trends Neurosci."},{"key":"10.1016\/j.ejphar.2019.05.004_bib26","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/S0169-328X(01)00217-0","article-title":"Group I metabotropic glutamate receptor activation increases phosphorylation of cAMP response element-binding protein, Elk-1, and extracellular signal-regulated kinases in rat dorsal striatum. Brain research","volume":"94","author":"Choe","year":"2001","journal-title":"Mol. Brain Res."},{"key":"10.1016\/j.ejphar.2019.05.004_bib27","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1002\/mds.870120306","article-title":"Unchanged basal ganglia N-acetylaspartate and glutamate in idiopathic Parkinson's disease measured by proton magnetic resonance spectroscopy","volume":"12","author":"Clarke","year":"1997","journal-title":"Mov. Disord."},{"key":"10.1016\/j.ejphar.2019.05.004_bib28","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1038\/nrn1763","article-title":"Metabotropic glutamate receptors in the basal ganglia motor circuit","volume":"6","author":"Conn","year":"2005","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.ejphar.2019.05.004_bib29","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1021\/jm025570j","article-title":"3-[(2-Methyl-1,3-thiazol-4-yl)ethynyl]-pyridine: a potent and highly selective metabotropic glutamate subtype 5 receptor antagonist with anxiolytic activity","volume":"46","author":"Cosford","year":"2003","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejphar.2019.05.004_bib30","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1056\/NEJM196702162760703","article-title":"Aromatic amino acids and modification of parkinsonism","volume":"276","author":"Cotzias","year":"1967","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejphar.2019.05.004_bib31","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.neurobiolaging.2017.09.006","article-title":"Altered mGluR5 binding potential and glutamine concentration in the 6-OHDA rat model of acute Parkinson's disease and levodopa-induced dyskinesia","volume":"61","author":"Crabbe","year":"2018","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.ejphar.2019.05.004_bib32","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.parkreldis.2005.05.008","article-title":"Amantadine reduces the duration of levodopa-induced dyskinesia: a randomized, double-blind, placebo-controlled study","volume":"11","author":"da Silva-Junior","year":"2005","journal-title":"Park. Relat. Disord."},{"key":"10.1016\/j.ejphar.2019.05.004_bib33","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1038\/npp.2008.129","article-title":"Metabotropic glutamate receptors 5 blockade reverses spatial memory deficits in a mouse model of Parkinson's disease","volume":"34","author":"De Leonibus","year":"2009","journal-title":"Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology"},{"key":"10.1016\/j.ejphar.2019.05.004_bib34","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.brainresbull.2005.12.009","article-title":"Effects of group I metabotropic glutamate receptors blockade in experimental models of Parkinson's disease","volume":"69","author":"Dekundy","year":"2006","journal-title":"Brain Res. Bull."},{"key":"10.1016\/j.ejphar.2019.05.004_bib35","article-title":"Reciprocal interaction between monoaminergic systems and the pedunculopontine nucleus: implication in the mechanism of L-DOPA","author":"Di Giovanni","year":"2018","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.ejphar.2019.05.004_bib36","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.bbr.2014.07.019","article-title":"Antidepressant-like effect of the mGluR5 antagonist MTEP in an astroglial degeneration model of depression","volume":"273","author":"Domin","year":"2014","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.ejphar.2019.05.004_bib37","doi-asserted-by":"crossref","first-page":"337","DOI":"10.2165\/00002512-199914050-00002","article-title":"Treating and preventing levodopa-induced dyskinesias: current and future strategies","volume":"14","author":"Durif","year":"1999","journal-title":"Drugs Aging"},{"key":"10.1016\/j.ejphar.2019.05.004_bib38","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1002\/mds.21475","article-title":"Levodopa-induced dyskinesias. Movement disorders","volume":"22","author":"Fabbrini","year":"2007","journal-title":"official journal of the Movement Disorder Society"},{"issue":"Suppl. 2","key":"10.1016\/j.ejphar.2019.05.004_bib39","first-page":"S56","article-title":"How do you treat motor complications in Parkinson's disease: medicine, surgery, or both?","volume":"64","author":"Fahn","year":"2008","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.ejphar.2019.05.004_bib40","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1111\/1440-1681.12410","article-title":"Selective blockade of mGlu5 metabotropic glutamate receptors is protective against hepatic mitochondrial dysfunction in 6-OHDA lesioned Parkinsonian rats","volume":"42","author":"Ferrigno","year":"2015","journal-title":"Clin. Exp. Pharmacol. Physiol."},{"key":"10.1016\/j.ejphar.2019.05.004_bib41","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1002\/mds.20936","article-title":"Translation of nondopaminergic treatments for levodopa-induced dyskinesia from MPTP-lesioned nonhuman primates to phase IIa clinical studies: keys to success and roads to failure","volume":"21","author":"Fox","year":"2006","journal-title":"Mov. Disord. : official journal of the Movement Disorder Society"},{"key":"10.1016\/j.ejphar.2019.05.004_bib42","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1016\/S0028-3908(99)00082-9","article-title":"2-Methyl-6-(phenylethynyl)-pyridine (MPEP), a potent, selective and systemically active mGlu5 receptor antagonist","volume":"38","author":"Gasparini","year":"1999","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.ejphar.2019.05.004_bib43","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.parkreldis.2011.01.008","article-title":"The acute antiparkinsonian and antidyskinetic effect of AFQ056, a novel metabotropic glutamate receptor type 5 antagonist, in L-Dopa-treated parkinsonian monkeys","volume":"17","author":"Gregoire","year":"2011","journal-title":"Park. Relat. Disord."},{"key":"10.1016\/j.ejphar.2019.05.004_bib44","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.parkreldis.2011.01.008","article-title":"The acute antiparkinsonian and antidyskinetic effect of AFQ056, a novel metabotropic glutamate receptor type 5 antagonist, in l-Dopa-treated parkinsonian monkeys","volume":"17","author":"Gr\u00e9goire","year":"2011","journal-title":"Park. Relat. Disord."},{"key":"10.1016\/j.ejphar.2019.05.004_bib45","first-page":"70","article-title":"White matter changes correlates of peripheral neuroinflammation in patients with Parkinson's disease","volume":"1","author":"Haghshomar","year":"2017","journal-title":"Neuroscience"},{"key":"10.1016\/j.ejphar.2019.05.004_bib46","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1128\/AAC.23.3.458","article-title":"Differences in side effects of amantadine hydrochloride and rimantadine hydrochloride relate to differences in pharmacokinetics","volume":"23","author":"Hayden","year":"1983","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejphar.2019.05.004_bib47","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1124\/pr.111.005678","article-title":"The Pharmacology of <span class=\"sc\">l<\/span>-DOPA-Induced Dyskinesia in Parkinson's Disease","volume":"65","author":"Huot","year":"2013","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.ejphar.2019.05.004_bib48","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1007\/s00702-011-0698-2","article-title":"Mechanisms underlying the onset and expression of levodopa-induced dyskinesia and their pharmacological manipulation","volume":"118","author":"Iravani","year":"2011","journal-title":"J. Neural Transm."},{"issue":"Suppl. 11","key":"10.1016\/j.ejphar.2019.05.004_bib49","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.1002\/mds.20458","article-title":"Motor fluctuations and dyskinesias in Parkinson's disease: clinical manifestations","volume":"20","author":"Jankovic","year":"2005","journal-title":"Mov. Disord. : official journal of the Movement Disorder Society"},{"issue":"Suppl. 4","key":"10.1016\/j.ejphar.2019.05.004_bib50","doi-asserted-by":"crossref","first-page":"S18","DOI":"10.1016\/S1353-8020(09)70829-6","article-title":"From the MPTP-treated primate to the treatment of motor complications in Parkinson's disease","volume":"15","author":"Jenner","year":"2009","journal-title":"Park. Relat. Disord."},{"key":"10.1016\/j.ejphar.2019.05.004_bib51","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1007\/s00213-009-1600-x","article-title":"Effect of the metabotropic glutamate antagonist MPEP on striatal expression of the Homer family proteins in levodopa-treated hemiparkinsonian rats","volume":"206","author":"Jimenez","year":"2009","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.ejphar.2019.05.004_bib52","doi-asserted-by":"crossref","first-page":"475","DOI":"10.2174\/187152709789824606","article-title":"Glutamate receptors as therapeutic targets for Parkinson's disease","volume":"8","author":"Johnson","year":"2009","journal-title":"CNS Neurol. Disord. - Drug Targets"},{"key":"10.1016\/j.ejphar.2019.05.004_bib53","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1124\/jpet.110.166629","article-title":"Reduction of L-DOPA-induced dyskinesia by the selective metabotropic glutamate receptor 5 antagonist 3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]pyridine in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque model of Parkinson's disease","volume":"333","author":"Johnston","year":"2010","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.ejphar.2019.05.004_bib54","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/j.neuroscience.2004.12.032","article-title":"Comparative effects of acute or chronic administration of levodopa to 6-hydroxydopamine-lesioned rats on the expression of glutamic acid decarboxylase in the neostriatum and GABAA receptors subunits in the substantia nigra, pars reticulata","volume":"132","author":"Katz","year":"2005","journal-title":"Neuroscience"},{"key":"10.1016\/j.ejphar.2019.05.004_bib55","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1002\/nbm.1141","article-title":"Glutamate measurement in Parkinson's disease using MRS at 3 T field strength","volume":"20","author":"Kickler","year":"2007","journal-title":"NMR Biomed."},{"key":"10.1016\/j.ejphar.2019.05.004_bib56","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2014.00157","article-title":"Cerebellum in levodopa-induced dyskinesias: the unusual suspect in the motor network","volume":"5","author":"Kishore","year":"2014","journal-title":"Front. Neurol."},{"key":"10.1016\/j.ejphar.2019.05.004_bib57","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1002\/mds.25859","article-title":"Combined fenobam and amantadine treatment promotes robust antidyskinetic effects in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned primate model of Parkinson's disease","volume":"29","author":"Ko","year":"2014","journal-title":"Mov. Disord. : official journal of the Movement Disorder Society"},{"key":"10.1016\/j.ejphar.2019.05.004_bib58","first-page":"91","article-title":"Amantadine and memantine are NMDA receptor antagonists with neuroprotective properties","volume":"43","author":"Kornhuber","year":"1994","journal-title":"J. Neural Transm. Suppl."},{"key":"10.1016\/j.ejphar.2019.05.004_bib59","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/s12640-009-9136-8","article-title":"Pretreatment with group I metabotropic glutamate receptors antagonists attenuates lethality induced by acute cocaine overdose and expression of sensitization to hyperlocomotor effect of cocaine in mice","volume":"19","author":"Kotlinska","year":"2011","journal-title":"Neurotox. Res."},{"key":"10.1016\/j.ejphar.2019.05.004_bib60","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1001\/archpsyc.1994.03950030035004","article-title":"Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses","volume":"51","author":"Krystal","year":"1994","journal-title":"Arch. Gen. Psychiatr."},{"key":"10.1016\/j.ejphar.2019.05.004_bib61","doi-asserted-by":"crossref","first-page":"6370","DOI":"10.1016\/j.bmcl.2013.09.059","article-title":"Scaffold hopping approach towards various AFQ-056 analogs as potent metabotropic glutamate receptor 5 negative allosteric modulators","volume":"23","author":"Kubas","year":"2013","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejphar.2019.05.004_bib62","doi-asserted-by":"crossref","first-page":"20","DOI":"10.3109\/00207454.2013.841685","article-title":"Mavoglurant (AFQ056) in combination with increased levodopa dosages in Parkinson's disease patients","volume":"126","author":"Kumar","year":"2016","journal-title":"Int. J. Neurosci."},{"key":"10.1016\/j.ejphar.2019.05.004_bib63","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1038\/mp.2015.132","article-title":"Alteration by p11 of mGluR5 localization regulates depression-like behaviors","volume":"20","author":"Lee","year":"2015","journal-title":"Mol. Psychiatr."},{"key":"10.1016\/j.ejphar.2019.05.004_bib64","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.nbd.2007.08.011","article-title":"Systemic administration of an mGluR5 antagonist, but not unilateral subthalamic lesion, counteracts l-DOPA-induced dyskinesias in a rodent model of Parkinson's disease","volume":"29","author":"Levandis","year":"2008","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.ejphar.2019.05.004_bib65","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1093\/brain\/awf128","article-title":"Dependence of subthalamic nucleus oscillations on movement and dopamine in Parkinson's disease","volume":"125","author":"Levy","year":"2002","journal-title":"Brain : J. Neurol."},{"key":"10.1016\/j.ejphar.2019.05.004_bib66","series-title":"Antidyskinetic Treatment with MTEP Affects Multiple Molecular Pathways in the Parkinsonian Striatum. Parkinson's Disease 2017","first-page":"5798734","author":"Lin","year":"2017"},{"key":"10.1016\/j.ejphar.2019.05.004_bib67","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1124\/jpet.108.136580","article-title":"ADX47273 [S-(4-fluoro-phenyl)-{3-[3-(4-fluoro-phenyl)-[1,2,4]-oxadiazol-5-yl]-piperidin-1- yl}-methanone]: a novel metabotropic glutamate receptor 5-selective positive allosteric modulator with preclinical antipsychotic-like and procognitive activities","volume":"327","author":"Liu","year":"2008","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.ejphar.2019.05.004_bib68","doi-asserted-by":"crossref","first-page":"3977","DOI":"10.1007\/s00213-015-3936-8","article-title":"Distinct pro-vigilant profile induced in rats by the mGluR5 potentiator LSN2814617","volume":"232","author":"Loomis","year":"2015","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.ejphar.2019.05.004_bib69","doi-asserted-by":"crossref","first-page":"5196","DOI":"10.1523\/JNEUROSCI.17-13-05196.1997","article-title":"Mice lacking metabotropic glutamate receptor 5 show impaired learning and reduced CA1 long-term potentiation (LTP) but normal CA3 LTP","volume":"17","author":"Lu","year":"1997","journal-title":"J. Neurosci. : the official journal of the Society for Neuroscience"},{"key":"10.1016\/j.ejphar.2019.05.004_bib70","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1002\/1531-8257(200009)15:5<873::AID-MDS1017>3.0.CO;2-I","article-title":"Beneficial effects of amantadine on L-dopa-induced dyskinesias in Parkinson's disease","volume":"15","author":"Luginger","year":"2000","journal-title":"Mov. Disord. : official journal of the Movement Disorder Society"},{"key":"10.1016\/j.ejphar.2019.05.004_bib71","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/S0891-0618(97)00051-3","article-title":"Differential plasma membrane distribution of metabotropic glutamate receptors mGluR1 alpha, mGluR2 and mGluR5, relative to neurotransmitter release sites","volume":"13","author":"Lujan","year":"1997","journal-title":"J. Chem. Neuroanat."},{"key":"10.1016\/j.ejphar.2019.05.004_bib72","doi-asserted-by":"crossref","first-page":"34","DOI":"10.3389\/fnana.2018.00034","article-title":"Stereological estimates of glutamatergic, GABAergic, and cholinergic neurons in the pedunculopontine and laterodorsal tegmental nuclei in the rat","volume":"12","author":"Luquin","year":"2018","journal-title":"Front. Neuroanat."},{"key":"10.1016\/j.ejphar.2019.05.004_bib73","series-title":"The Effects of L-DOPA on Regional Cerebral Glucose Utilization in Rats with Unilateral Lesions of the Substantia Nigra","author":"M. Trugman","year":"1986"},{"key":"10.1016\/j.ejphar.2019.05.004_bib74","doi-asserted-by":"crossref","first-page":"5925","DOI":"10.1523\/JNEUROSCI.21-16-05925.2001","article-title":"Metabotropic glutamate receptors 1 and 5 differentially regulate CA1 pyramidal cell function","volume":"21","author":"Mannaioni","year":"2001","journal-title":"J. Neurosci. : the official journal of the Society for Neuroscience"},{"key":"10.1016\/j.ejphar.2019.05.004_bib75","series-title":"Selective Activation of Group I Metabotropic Glutamate Receptors Upregulates Preprodynorphin, Substance P, and Preproenkephalin mRNA Expression in Rat Dorsal Striatum","author":"Mao","year":"2001"},{"key":"10.1016\/j.ejphar.2019.05.004_bib76","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1124\/mol.62.3.473","article-title":"Glutamate cascade to cAMP response element-binding protein phosphorylation in cultured striatal neurons through calcium-coupled group I metabotropic glutamate receptors","volume":"62","author":"Mao","year":"2002","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.ejphar.2019.05.004_bib77","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1046\/j.1471-4159.2003.01750.x","article-title":"Metabotropic glutamate receptor 5-regulated Elk-1 phosphorylation and immediate early gene expression in striatal neurons","volume":"85","author":"Mao","year":"2003","journal-title":"J. Neurochem."},{"key":"10.1016\/j.ejphar.2019.05.004_bib78","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.ejphar.2012.02.036","article-title":"Investigation of the antidyskinetic site of action of metabotropic and ionotropic glutamate receptor antagonists. Intracerebral infusions in 6-hydroxydopamine-lesioned rats with levodopa-induced dyskinesia","volume":"683","author":"Maranis","year":"2012","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2019.05.004_bib79","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1136\/jnnp.36.1.10","article-title":"Treatment of Parkinson's disease with levodopa combined with L-alpha-methyldopahydrazine, an inhibitor of extracerebral DOPA decarboxylase","volume":"36","author":"Marsden","year":"1973","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.ejphar.2019.05.004_bib80","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1007\/s11682-017-9712-0","article-title":"Effects of common GRM5 genetic variants on cognition, hippocampal volume and mGluR5 protein levels in schizophrenia","volume":"12","author":"Matosin","year":"2018","journal-title":"Brain imaging and behavior"},{"key":"10.1016\/j.ejphar.2019.05.004_bib81","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1111\/j.1471-4159.2007.04456.x","article-title":"Antagonism of metabotropic glutamate receptor type 5 attenuates l-DOPA-induced dyskinesia and its molecular and neurochemical correlates in a rat model of Parkinson's disease","volume":"101","author":"Mela","year":"2007","journal-title":"J. Neurochem."},{"key":"10.1016\/j.ejphar.2019.05.004_bib82","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1111\/j.1471-4159.2007.04456.x","article-title":"Antagonism of metabotropic glutamate receptor type 5 attenuates l-DOPA-induced dyskinesia and its molecular and neurochemical correlates in a rat model of Parkinson's disease","volume":"101","author":"Mela","year":"2007","journal-title":"J. Neurochem."},{"key":"10.1016\/j.ejphar.2019.05.004_bib83","doi-asserted-by":"crossref","first-page":"144","DOI":"10.3389\/fneur.2014.00144","article-title":"Pharmacological treatments inhibiting levodopa-induced dyskinesias in MPTP-lesioned monkeys: brain glutamate biochemical correlates","volume":"5","author":"Morin","year":"2014","journal-title":"Front. Neurol."},{"key":"10.1016\/j.ejphar.2019.05.004_bib84","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1016\/j.neuropharm.2009.12.024","article-title":"Effect of the metabotropic glutamate receptor type 5 antagonists MPEP and MTEP in parkinsonian monkeys","volume":"58","author":"Morin","year":"2010","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.ejphar.2019.05.004_bib85","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.neuropharm.2012.07.036","article-title":"MPEP, an mGlu5 receptor antagonist, reduces the development of L-DOPA-induced motor complications in de novo parkinsonian monkeys: biochemical correlates","volume":"66","author":"Morin","year":"2013","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.ejphar.2019.05.004_bib86","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.neuropharm.2013.05.028","article-title":"Chronic treatment with MPEP, an mGlu5 receptor antagonist, normalizes basal ganglia glutamate neurotransmission in L-DOPA-treated parkinsonian monkeys","volume":"73","author":"Morin","year":"2013","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.ejphar.2019.05.004_bib87","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.neuroscience.2003.08.010","article-title":"Normalization of glutamate decarboxylase gene expression in the entopeduncular nucleus of rats with a unilateral 6-hydroxydopamine lesion correlates with increased gabaergic input following intermittent but not continuous levodopa","volume":"123","author":"Nielsen","year":"2004","journal-title":"Neuroscience"},{"issue":"Suppl. 3","key":"10.1016\/j.ejphar.2019.05.004_bib88","doi-asserted-by":"crossref","first-page":"S580","DOI":"10.1002\/mds.22037","article-title":"Pharmacokinetics and pharmacodynamics of levodopa","volume":"23","author":"Nutt","year":"2008","journal-title":"Mov. Disord. : official journal of the Movement Disorder Society"},{"key":"10.1016\/j.ejphar.2019.05.004_bib89","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1016\/j.neurobiolaging.2009.07.014","article-title":"Metabotropic glutamate receptor type 5 in levodopa-induced motor complications","volume":"32","author":"Ouattara","year":"2011","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.ejphar.2019.05.004_bib90","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1056\/NEJM197201062860102","article-title":"Levodopa in Parkinsonism: potentiation of central effects with a peripheral inhibitor","volume":"286","author":"Papavasiliou","year":"1972","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejphar.2019.05.004_bib91","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1016\/S0140-6736(70)91211-0","article-title":"Amantadine dosage in treatment of Parkinson's disease","volume":"1","author":"Parkes","year":"1970","journal-title":"Lancet"},{"key":"10.1016\/j.ejphar.2019.05.004_bib92","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0028-3908(94)00129-G","article-title":"The metabotropic glutamate receptors: structure and functions","volume":"34","author":"Pin","year":"1995","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.ejphar.2019.05.004_bib93","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S0028-3908(03)00137-0","article-title":"Targeting striatal cholinergic interneurons in Parkinson's disease: focus on metabotropic glutamate receptors","volume":"45","author":"Pisani","year":"2003","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.ejphar.2019.05.004_bib94","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1124\/jpet.105.089839","article-title":"Fenobam: a clinically validated nonbenzodiazepine anxiolytic is a potent, selective, and noncompetitive mGlu5 receptor antagonist with inverse agonist activity","volume":"315","author":"Porter","year":"2005","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.ejphar.2019.05.004_bib95","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1038\/nrneurol.2016.152","article-title":"Advances in markers of prodromal Parkinson disease","volume":"12","author":"Postuma","year":"2016","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.ejphar.2019.05.004_bib96","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0014020","article-title":"Alterations in mGluR5 expression and signaling in Lewy body disease and in transgenic models of alpha-synucleinopathy--implications for excitotoxicity","volume":"5","author":"Price","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.ejphar.2019.05.004_bib97","doi-asserted-by":"crossref","first-page":"4589","DOI":"10.1523\/JNEUROSCI.3451-13.2014","article-title":"Intracellular mGluR5 can mediate synaptic plasticity in the hippocampus","volume":"34","author":"Purgert","year":"2014","journal-title":"J. Neurosci. : the official journal of the Society for Neuroscience"},{"key":"10.1016\/j.ejphar.2019.05.004_bib98","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1016\/j.parkreldis.2014.05.003","article-title":"Use of metabotropic glutamate 5-receptor antagonists for treatment of levodopa-induced dyskinesias","volume":"20","author":"Rascol","year":"2014","journal-title":"Park. Relat. Disord."},{"key":"10.1016\/j.ejphar.2019.05.004_bib99","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1523\/JNEUROSCI.4974-09.2010","article-title":"Metabotropic glutamate receptor-mediated cell signaling pathways are altered in a mouse model of Huntington's disease","volume":"30","author":"Ribeiro","year":"2010","journal-title":"J. Neurosci. : the official journal of the Society for Neuroscience"},{"key":"10.1016\/j.ejphar.2019.05.004_bib100","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1111\/j.1460-9568.2004.03591.x","article-title":"Chronic L-DOPA treatment increases extracellular glutamate levels and GLT1 expression in the basal ganglia in a rat model of Parkinson's disease","volume":"20","author":"Robelet","year":"2004","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.ejphar.2019.05.004_bib101","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.nbd.2010.05.001","article-title":"A mGluR5 antagonist under clinical development improves L-DOPA-induced dyskinesia in parkinsonian rats and monkeys","volume":"39","author":"Rylander","year":"2010","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.ejphar.2019.05.004_bib102","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1124\/jpet.108.150425","article-title":"Pharmacological modulation of glutamate transmission in a rat model of L-DOPA-induced dyskinesia: effects on motor behavior and striatal nuclear signaling","volume":"330","author":"Rylander","year":"2009","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.ejphar.2019.05.004_bib103","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1016\/j.neurobiolaging.2007.02.005","article-title":"mGluR5 metabotropic glutamate receptors and dyskinesias in MPTP monkeys","volume":"29","author":"Samadi","year":"2008","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.ejphar.2019.05.004_bib104","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.neuroimage.2008.04.170","article-title":"Enhanced binding of metabotropic glutamate receptor type 5 (mGluR5) PET tracers in the brain of parkinsonian primates","volume":"42","author":"Sanchez-Pernaute","year":"2008","journal-title":"Neuroimage"},{"key":"10.1016\/j.ejphar.2019.05.004_bib105","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1515\/revneuro-2016-0068","article-title":"Neurotransmission systems in Parkinson's disease","volume":"28","author":"Sanjari Moghaddam","year":"2017","journal-title":"Rev. Neurosci."},{"key":"10.1016\/j.ejphar.2019.05.004_bib106","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1111\/jnc.13291","article-title":"Adenosine A(2)A receptors permit mGluR5-evoked tyrosine phosphorylation of NR2B (Tyr1472) in rat hippocampus: a possible key mechanism in NMDA receptor modulation","volume":"135","author":"Sarantis","year":"2015","journal-title":"J. Neurochem."},{"key":"10.1016\/j.ejphar.2019.05.004_bib107","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.coph.2018.03.003","article-title":"mGlu receptors in the treatment of Parkinson's disease and L-DOPA-induced dyskinesia","volume":"38","author":"Sebastianutto","year":"2018","journal-title":"Curr. Opin. Pharmacol."},{"key":"10.1016\/j.ejphar.2019.05.004_bib108","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.expneurol.2016.03.024","article-title":"Enkephalin and dynorphin neuropeptides are differently correlated with locomotor hypersensitivity and levodopa-induced dyskinesia in parkinsonian rats","volume":"280","author":"Sgroi","year":"2016","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.ejphar.2019.05.004_bib109","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1038\/nn.4028","article-title":"mGluR5 in the nucleus accumbens is critical for promoting resilience to chronic stress","volume":"18","author":"Shin","year":"2015","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.ejphar.2019.05.004_bib110","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1016\/j.neurobiolaging.2014.12.037","article-title":"The role of pallidal serotonergic function in Parkinson's disease dyskinesias: a positron emission tomography study","volume":"36","author":"Smith","year":"2015","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.ejphar.2019.05.004_bib111","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.nbd.2005.04.001","article-title":"Denervation and repeated L-DOPA induce complex regulatory changes in neurochemical phenotypes of striatal neurons: implication of a dopamine D1-dependent mechanism","volume":"20","author":"St-Hilaire","year":"2005","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.ejphar.2019.05.004_bib112","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1002\/mds.25561","article-title":"AFQ056 in Parkinson patients with levodopa-induced dyskinesia: 13-week, randomized, dose-finding study","volume":"28","author":"Stocchi","year":"2013","journal-title":"Mov. Disord. : official journal of the Movement Disorder Society"},{"issue":"Suppl. 3","key":"10.1016\/j.ejphar.2019.05.004_bib113","doi-asserted-by":"crossref","first-page":"S599","DOI":"10.1002\/mds.22052","article-title":"Treatment of levodopa-induced motor complications","volume":"23","author":"Stocchi","year":"2008","journal-title":"Mov. Disord. : official journal of the Movement Disorder Society"},{"key":"10.1016\/j.ejphar.2019.05.004_bib114","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1023\/A:1020609530444","article-title":"A proton magnetic resonance spectroscopy study of the striatum and cerebral cortex in Parkinson's disease","volume":"14","author":"Taylor-Robinson","year":"1999","journal-title":"Metab. Brain Dis."},{"key":"10.1016\/j.ejphar.2019.05.004_bib115","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1136\/pgmj.2006.054759","article-title":"Levodopa-induced dyskinesia in Parkinson's disease: clinical features, pathogenesis, prevention and treatment","volume":"83","author":"Thanvi","year":"2007","journal-title":"Postgrad. Med."},{"key":"10.1016\/j.ejphar.2019.05.004_bib116","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1002\/mds.26659","article-title":"A phase 2A trial of the novel mGluR5-negative allosteric modulator dipraglurant for levodopa-induced dyskinesia in Parkinson's disease. Movement disorders","volume":"31","author":"Tison","year":"2016","journal-title":"official journal of the Movement Disorder Society"},{"key":"10.1016\/j.ejphar.2019.05.004_bib117","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1002\/mds.26585","article-title":"Mavoglurant in Parkinson's patients with l-Dopa-induced dyskinesias: two randomized phase 2 studies","volume":"31","author":"Trenkwalder","year":"2016","journal-title":"Mov. Disord. : official journal of the Movement Disorder Society"},{"key":"10.1016\/j.ejphar.2019.05.004_bib118","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1111\/j.1460-9568.2005.04362.x","article-title":"Neuroprotective effects of metabotropic glutamate receptor ligands in a 6-hydroxydopamine rodent model of Parkinson's disease","volume":"22","author":"Vernon","year":"2005","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.ejphar.2019.05.004_bib119","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1111\/j.1471-4159.2007.04860.x","article-title":"Subtype selective antagonism of substantia nigra pars compacta Group I metabotropic glutamate receptors protects the nigrostriatal system against 6-hydroxydopamine toxicity in vivo","volume":"103","author":"Vernon","year":"2007","journal-title":"J. Neurochem."},{"key":"10.1016\/j.ejphar.2019.05.004_bib120","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1016\/S1474-4422(09)70287-X","article-title":"Chronic dopaminergic stimulation in Parkinson's disease: from dyskinesias to impulse control disorders","volume":"8","author":"Voon","year":"2009","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.ejphar.2019.05.004_bib121","doi-asserted-by":"crossref","first-page":"3763","DOI":"10.1523\/JNEUROSCI.4574-04.2005","article-title":"Metabotropic glutamate receptors and dopamine receptors cooperate to enhance extracellular signal-regulated kinase phosphorylation in striatal neurons","volume":"25","author":"Voulalas","year":"2005","journal-title":"J. Neurosci."},{"key":"10.1016\/j.ejphar.2019.05.004_bib122","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2012.00189","article-title":"Group I metabotropic glutamate receptor-mediated gene transcription and implications for synaptic plasticity and diseases","volume":"3","author":"Wang","year":"2012","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ejphar.2019.05.004_bib123","doi-asserted-by":"crossref","first-page":"262","DOI":"10.3389\/fnagi.2018.00262","article-title":"Effects of mGluR5 antagonists on Parkinson's patients with L-dopa-induced dyskinesia: a systematic review and meta-analysis of randomized controlled trials","volume":"10","author":"Wang","year":"2018","journal-title":"Front. Aging Neurosci."},{"key":"10.1016\/j.ejphar.2019.05.004_bib124","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1172\/JCI106611","article-title":"Modification of the cardiovascular effects of l-dopa by decarboxylase inhibitors","volume":"50","author":"Watanabe","year":"1971","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.ejphar.2019.05.004_bib125","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1046\/j.0953-816x.2001.01743.x","article-title":"Persistent changes in striatal gene expression induced by long-term l-DOPA treatment in a rat model of Parkinson's disease","volume":"14","author":"Westin","year":"2001","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.ejphar.2019.05.004_bib126","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1016\/j.biopsych.2006.11.032","article-title":"Spatiotemporal pattern of striatal ERK1\/2 phosphorylation in a rat model of L-DOPA-induced dyskinesia and the role of dopamine D1 receptors","volume":"62","author":"Westin","year":"2007","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.ejphar.2019.05.004_bib127","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1016\/j.neuroscience.2009.07.060","article-title":"Metabotropic glutamate mGluR5 receptor blockade opposes abnormal involuntary movements and the increases in glutamic acid decarboxylase mRNA levels induced by l-DOPA in striatal neurons of 6-hydroxydopamine-lesioned rats","volume":"163","author":"Yamamoto","year":"2009","journal-title":"Neuroscience"}],"container-title":["European Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299919303085?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299919303085?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T22:28:10Z","timestamp":1757975290000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014299919303085"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7]]},"references-count":127,"alternative-id":["S0014299919303085"],"URL":"https:\/\/doi.org\/10.1016\/j.ejphar.2019.05.004","relation":{},"ISSN":["0014-2999"],"issn-type":[{"value":"0014-2999","type":"print"}],"subject":[],"published":{"date-parts":[[2019,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pathophysiological clues to therapeutic applications of glutamate mGlu5 receptor antagonists in levodopa-induced dyskinesia","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejphar.2019.05.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}